BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31324389)

  • 21. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.
    Davis RE; Brown KD; Siebenlist U; Staudt LM
    J Exp Med; 2001 Dec; 194(12):1861-74. PubMed ID: 11748286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
    Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
    Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
    Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
    Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Dobashi A
    J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.
    Zhang YA; Yang X; Yao J; Ren Y; Liu P
    Dis Markers; 2022; 2022():3276925. PubMed ID: 35774848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene.
    Chao CN; Huang YL; Lin MC; Fang CY; Shen CH; Chen PL; Wang M; Chang D; Tseng CE
    J Transl Med; 2015 Jan; 13():29. PubMed ID: 25623859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of bcl-6 protein expression and gene rearrangement in diffuse large B-cell lymphoma].
    Min DL; Xia HL; Zhou XY; Sun MH; Yang WT; Zhang TM; Zheng AH; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):327-31. PubMed ID: 16185497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteomic analysis in diffuse large B-cell lymphoma identifies dysregulated tumor microenvironment proteins in non-GCB/ABC subtype patients.
    Bram Ednersson S; Stern M; Fagman H; Nilsson-Ehle H; Hasselblom S; Thorsell A; Andersson PO
    Leuk Lymphoma; 2021 Oct; 62(10):2360-2373. PubMed ID: 34114929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis.
    Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R;
    Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.
    Knittel G; Liedgens P; Korovkina D; Pallasch CP; Reinhardt HC
    Eur J Haematol; 2016 Dec; 97(6):499-510. PubMed ID: 27526684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
    Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma.
    Verma A; Jiang Y; Du W; Fairchild L; Melnick A; Elemento O
    Genome Med; 2015 Nov; 7():110. PubMed ID: 26521025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
    Zheng W; Lin Q; Issah MA; Liao Z; Shen J
    BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases.
    Tzankov A; Pehrs AC; Zimpfer A; Ascani S; Lugli A; Pileri S; Dirnhofer S
    J Clin Pathol; 2003 Oct; 56(10):747-52. PubMed ID: 14514777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Potential Therapeutic Targets for Plasmablastic Lymphoma Through Gene Expression Analysis: Insights into RAS and Wnt Signaling Pathways.
    Mansoor A; Kamran H; Akhter A; Seno R; Torlakovic EE; Roshan TM; Shabani-Rad MT; Elyamany G; Minoo P; Stewart D
    Mod Pathol; 2023 Aug; 36(8):100198. PubMed ID: 37105495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p63 protein expression in high risk diffuse large B-cell lymphoma.
    Hallack Neto AE; Siqueira SA; Dulley FL; Ruiz MA; Chamone DA; Pereira J
    J Clin Pathol; 2009 Jan; 62(1):77-9. PubMed ID: 19103865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary central nervous system diffuse large B-cell lymphoma shows an activated B-cell-like phenotype with co-expression of C-MYC, BCL-2, and BCL-6.
    Li X; Huang Y; Bi C; Yuan J; He H; Zhang H; Yu Q; Fu K; Li D
    Pathol Res Pract; 2017 Jun; 213(6):659-665. PubMed ID: 28552541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma.
    Skacel M; Ross CW; Hsi ED
    Histopathology; 2000 Jul; 37(1):10-8. PubMed ID: 10931213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.